Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Clinical Early Stages(T2N0, T1 - 2N1, T3N0 AND T3N1) Non-Small Cell Lung Cancer (NSCLC)

NCT00191126 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00191126
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00191126 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Clinical Early Stages(T2N0, T1 - 2N1, T3N0 AND T3N1) Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2000
Completion date
September 30, 2007
Enrollment
263 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer